More Than Good Intentions: Diversity, Equity & Inclusion Requires a Program-Level, Strategic Framework

September 9, 2021

Sponsors understand the importance of diversity, equity and inclusion (DE&I) efforts and have begun to implement them in their trials, but diversity in clinical trials has yet to be achieved.

To address this gap between aspiration and execution, sponsors--as well as sites and CROs-- must recognize that DE&I is not merely another project. Neither is it a series of tactics. It is a systemic, top down transformation that must be managed strategically at the program level. The DE&I strategy must be communicated and implemented across your trial sites, including referral sites. It needs to extend into the nearby community-based sources of potential patients. Most importantly, no one can execute a diversity strategy alone.

Download the whitepaper to continue reading...

Previous Flipbook
Delivering CNS Trials Requires Specialized Clinical Knowledge
Delivering CNS Trials Requires Specialized Clinical Knowledge

Next Flipbook
The Top 5 Benefits of Outsourcing Expert Committee Management to an Independent Provider
The Top 5 Benefits of Outsourcing Expert Committee Management to an Independent Provider